Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,061 INR | -0.91% | +2.64% | +24.35% |
Apr. 29 | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.35% | 3.62B | |
+20.56% | 43.75B | |
+25.54% | 22.06B | |
+13.30% | 14.46B | |
+13.24% | 13.62B | |
+39.26% | 11.61B | |
-9.82% | 6.9B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+9.64% | 5.32B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Nomura Adjusts Glenmark Pharmaceuticals' Price Target to INR633 From INR580, Keeps at Buy